Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

TENNESSEE PAIN MANAGEMENT AND REHABILITATION PC

NPI: 1437459047 · DECHERD, TN 37324 · Interventional Pain Medicine Physician · NPI assigned 10/29/2010

$121K
Total Medicaid Paid
6,962
Total Claims
5,738
Beneficiaries
6
Codes Billed
2018-01
First Month
2019-06
Last Month

Provider Details

Authorized OfficialKUHAR, WILLIAM (OWNER, SECRETARY)
NPI Enumeration Date10/29/2010

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,079 $104K
2019 1,883 $17K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 3,740 3,066 $85K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 2,049 1,642 $25K
80305 1,047 913 $8K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 41 41 $3K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 31 30 $345.94
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 54 46 $43.02